Structural Heart · Device Innovation

Nickel-Free and Circular: What the Siegel TAVI Valve's Early Data Mean for Practice and Portfolio

A novel balloon-expandable, nickel-free transcatheter valve posted low pacemaker rates and stable two-year hemodynamics at New York Valves 2026 — and a $1.5 billion industry bet suggests Wall Street is paying attention too.

A new entrant in the crowded transcatheter aortic valve implantation (TAVI) field is drawing attention for solving two problems at once.

The Siegel valve, developed by MiRus, is built from a proprietary molybdenum-rhenium alloy rather than the nickel-titanium nitinol used in most commercial platforms.

That single material change addresses an estimated 20% of Americans with nickel sensitivity who have historically been poor candidates for self-expanding nitinol valves.

Early feasibility and first-in-human data presented at New York Valves 2026 showed acute procedural success in all cases, a low new-pacemaker rate, and hemodynamics that held steady out to two years.

For practicing interventional and general cardiologists, the device is not yet commercially available, but its design logic and its emerging industry backing are worth understanding now.

Case Vignette

A 78-year-old patient with severe, symptomatic aortic stenosis and a documented history of a contact dermatitis reaction to a nickel-containing orthopedic implant is referred for valve evaluation.

Computed tomography shows a heavily calcified, mildly bicuspid annulus with iliofemoral vessels too small for standard 14-Fr delivery systems.

The heart team is hesitant to proceed with a nitinol-frame self-expanding valve given the allergy history, and the patient is anxious about being "turned away" from a minimally invasive option.

This is the patient population in which investigational nickel-free, low-profile platforms such as the Siegel valve are being studied, and a structural heart referral for trial screening — rather than default surgical referral — may be appropriate where enrollment is open.

An Engineering Story Built Around Three Problems

Conventional self-expanding TAVI frames rely on nitinol for its shape-memory and superelastic properties, but nitinol contains nickel and titanium and can foreshorten during deployment.

The Siegel platform instead uses a molybdenum-rhenium "MoRe" superalloy with vertical stent rods designed to eliminate foreshortening entirely, which the developer says improves positioning precision and may lower conduction-system trauma.

The frame is coated with nitric oxide, a strategy intended to support endothelial healing and reduce the inflammatory response that can contribute to leaflet thrombosis.

Commissural alignment flags built into the frame let operators visualize and rotate the valve into the optimal commissural position before final deployment, rather than relying on post-hoc imaging correction.

The valve also arrives pre-mounted on its delivery balloon, removing a manual crimping step that exists with some other balloon-expandable systems.

Delivery occurs through an 8-Fr expandable sheath, roughly half the profile of many currently marketed systems, which may extend transfemoral eligibility to patients with smaller-caliber peripheral vessels, including more women.

Table 1. Siegel Valve Design Features vs. Two Commercial Comparators

Feature	Siegel (MiRus, investigational)	Sapien 3 family (Edwards Lifesciences)	Evolut family (Medtronic)
Frame alloy	Molybdenum-rhenium (nickel-free)	Cobalt-chromium	Nitinol (nickel-titanium)
Deployment mechanism	Balloon-expandable	Balloon-expandable	Self-expanding
Delivery sheath	8-Fr expandable	14-Fr (eSheath)	14-Fr (self-expanding system)
Foreshortening	Designed to eliminate	Standard for class	Greater, by design (supra-annular)
Leaflet ellipticity ratio, tricuspid	1.02 (reported)	1.09 (reported)	1.20 (reported)
Sizes available in study	23, 26, 29 mm	20–29 mm range	23–34 mm range
Regulatory status	Investigational (STAR trial enrolling)	FDA-approved, commercial	FDA-approved, commercial

Ellipticity values closer to 1.0 indicate a more circular valve orifice, which investigators have associated with more favorable durability profiles. Figures for Siegel and comparator devices as reported by the presenting investigator at New York Valves 2026; comparator specifications are manufacturer-published.

What the First-in-Human and Feasibility Data Showed

The pooled experience includes five patients treated in a first-in-human cohort in Chile and 30 patients enrolled in a nine-site United States early feasibility study, for a combined 35 patients.

Mean age in the feasibility cohort was 76 years, 57% were male, mean Society of Thoracic Surgeons score was 2.81%, and 80% were classified as low surgical risk.

All procedures used transfemoral access, positioning and commissural alignment were achieved in every case, and mean time from sheath insertion to valve deployment was 15 minutes.

One death unrelated to the valve occurred by six months (under 1%), and three patients required a new permanent pacemaker (8.5%).

No strokes, annular ruptures, need for a second valve, reinterventions, major vascular complications, significant bleeding, more-than-moderate aortic regurgitation, or acute kidney injury were reported through the available follow-up.

Three of the 35 patients had previously been declined for TAVI elsewhere specifically because of severe nickel allergy.

First-in-human cohort (to 2 years)

Baseline

40.1 mmHg

Follow-up

7.8 mmHg

EFS cohort, 26-mm valve (to 6 months)

Baseline

41.2 mmHg

Follow-up

7.0 mmHg

EFS cohort, 23-mm valve (to 6 months)

Baseline

39.0 mmHg

Follow-up

8.3 mmHg

Baseline mean gradientFollow-up mean gradient

Figure 1. Mean transvalvular gradients fell substantially across all cohorts and valve sizes and, notably, did not show the double-digit residual gradients sometimes seen with smaller valve sizes from other platforms in patients with small annuli.

Aortic valve area improved in parallel, increasing from 0.8 to 2.0 cm² in the first-in-human cohort, from 0.8 to 2.5 cm² for the 26-mm EFS valve, and from 0.7 to 2.2 cm² for the 23-mm EFS valve.

The presenting investigator described the stability of these gradients and areas out to two years as the most clinically important early signal, particularly because smaller valve sizes are typically where prosthesis-patient mismatch becomes most apparent with existing platforms.

The Circularity-Durability Hypothesis

A recurring theme at the session was whether a valve with high radial force and minimal recoil might be more prone to annular injury in heavily calcified anatomy.

The presenting investigator argued that rupture risk relates more to oversizing strategy than to absolute radial force, and that because the Siegel frame does not require hyperinflation to compensate for recoil, the balloon can target a narrower 0–2% oversizing range.

On that basis, the feasibility study enrolled patients with aortic valve calcium scores up to 7,000 Agatston units, including bicuspid anatomy, contingent on heart-team and review-committee sign-off.

Investigators also pointed to valve "circularity" — how closely the deployed orifice approximates a true circle — as an underappreciated durability variable, since an elliptical orifice can produce regions of leaflet stress concentration.

Siegel, tricuspid

1.02

Siegel, bicuspid

1.03

Sapien 3, tricuspid

1.09

Sapien 3, bicuspid

1.12

Evolut, tricuspid

1.20

Evolut, bicuspid

1.30

Figure 2. Ellipticity ratio by valve and annular morphology, as reported by the presenting investigator at New York Valves 2026. A ratio of 1.00 represents a perfect circle; longer bars indicate a more elliptical, less circular deployed frame.

Leaflet sourcing was also highlighted as a differentiator, with the developer reportedly applying selective screening of porcine pericardial tissue for thickness uniformity and collagen cross-linkage before use.

Whether these design choices translate into superior long-term durability remains unproven, and panel discussants were careful to note that the benchmark — the Sapien 3 platform's own long-term performance — is a high bar.

Where the Program Goes Next

The pivotal STAR trial is now enrolling roughly 1,000 to 1,025 patients with severe, symptomatic aortic stenosis across the risk spectrum, randomizing them to the Siegel valve or a commercially available balloon-expandable or self-expanding device.

The primary endpoint is a composite of mortality, stroke, and cardiovascular hospitalization at one year.

Current access is limited to enrolling STAR trial sites, and the device has no FDA approval or commercial pricing at this time.

Operators interested in offering the technology to nickel-allergic or small-vessel patients should look for STAR trial participation among regional structural heart programs rather than expecting near-term commercial access.

The Investing Angle: A $1.5 Billion Signal

In May 2026, Boston Scientific invested $1.5 billion in MiRus, acquiring a 34% equity stake along with an exclusive option to acquire the Siegel TAVR business outright for an additional $3 billion if the program hits clinical and regulatory milestones.

The move marks Boston Scientific's third attempt to break into the TAVI market after its earlier Acurate and Lotus Edge platforms were discontinued, and it gives the company a stake in a technology explicitly positioned as nickel-free and differentiated rather than a me-too valve.

For a physician-investor audience, the deal is a reminder that device-maker valuations can move on early-stage structural heart bets long before FDA approval or revenue materializes.

The broader TAVI market remains a duopoly in practice, with Edwards Lifesciences and Medtronic together accounting for the overwhelming majority of commercial implants, which is the incumbency Boston Scientific is trying to disrupt with this investment.

Table 2. Public Companies With a Direct Stake in This Story

Company	Ticker	Recent share price	Relevance to Siegel/TAVI
Boston Scientific Corporation	NYSE: BSX	~$43–46	$1.5B investment for 34% stake in MiRus; exclusive option to acquire Siegel TAVR business for $3B more
Edwards Lifesciences Corporation	NYSE: EW	~$90–91	Maker of the Sapien 3 family; dominant incumbent balloon-expandable platform
Medtronic plc	NYSE: MDT	~$80–81	Maker of the Evolut family; dominant incumbent self-expanding platform

Prices are approximate and reflect late-June 2026 trading levels; they will move and should be verified independently before any investment decision. This table is general financial education, not personalized investment advice.

On reimbursement, it is worth noting that none of the commercial valves' device-level acquisition costs are publicly itemized, since CMS bundles transcatheter valve procedures into inpatient diagnosis-related group payments rather than reimbursing the valve as a separate line item.

Total one-year episode costs for balloon-expandable TAVR have been estimated in the $80,000 range in published cost-utility analyses, a figure that includes the device, procedure, hospitalization, and follow-up rather than device acquisition cost alone.

Should the Siegel valve reach approval, its eventual pricing will likely be set competitively against this established episode-cost backdrop rather than as a stand-alone premium product.

Bottom Line

• The Siegel valve is an investigational, nickel-free, balloon-expandable TAVI platform showing low pacemaker rates, stable two-year hemodynamics, and a markedly more circular deployed frame than two leading commercial comparators in early data.
• It is not yet FDA-approved; access is currently limited to the enrolling STAR pivotal trial, and clinicians should not expect near-term commercial availability.
• The device may be particularly relevant for patients with documented nickel allergy or small peripheral vessels once broader access is available.
• Boston Scientific's $1.5 billion equity investment and acquisition option signal industry confidence but do not substitute for pivotal-trial efficacy and durability data, which will not mature for several years.

References

1. Why Boston Scientific is betting $1.5B on this TAVR superalloy. Medical Design & Outsourcing, June 2026.
2. MiRus treats first patients in STAR trial of Siegel 8-French heart valve. Medical Device Network, April 2026.
3. What's Going to Be Hot at New York Valves 2026. TCTMD, June 2026.
4. Target: Aortic Stenosis initiative. American Heart Association.
5. Boston Scientific Corporation (BSX) stock overview. StockAnalysis.com.
6. Edwards Lifesciences Corporation (EW) stock overview. StockAnalysis.com.
7. Medtronic plc (MDT) stock overview. StockAnalysis.com.
8. Transcatheter SAPIEN 3 Ultra valve. Edwards Lifesciences.
9. SAPIEN 3 Valve Demonstrates Significant Cost Savings Over Surgery in Intermediate-Risk Patients. Diagnostic and Interventional Cardiology.

This article is intended for physician education and general information purposes only. It does not constitute clinical, legal, or financial advice, and it should not be used as the sole basis for any patient-care or investment decision. Device availability, regulatory status, and pricing described here reflect publicly available information as of late June 2026 and are subject to change. Readers should consult primary trial data, current prescribing/use information, and a qualified financial advisor before acting on any information presented.

Statin Deprescribing: A Practical Algorithm for Patients With Limited Life Expectancy

A 2026 review of 56 studies builds the evidence case for stopping statins in frail, multimorbid, and end-of-life patients — here is what the data show and how to apply it.

Cardiology Practice · Evidence Review · June 2026

The reflexive instinct in cardiology is to keep patients on a statin indefinitely once it has been started.

A newly published comprehensive review in Internal Medicine Journal challenges that default for a specific population: patients whose limited life expectancy or significant multimorbidity shifts the risk-benefit calculus away from long-term prevention.

Statins reduce low-density lipoprotein cholesterol to prevent atherosclerotic cardiovascular disease, but in patients with shortened prognosis the long-term benefits shrink while the risks of harm grow proportionally larger.

The investigators behind this review systematically searched PubMed in November 2024 using the terms "statins AND (deprescribing OR deprescription)."

Fifty-six studies met inclusion criteria, spanning sample sizes from a single patient to more than 212,000.

This article synthesizes that evidence base alongside a companion 2026 meta-analysis in BMC Geriatrics and a landmark randomized trial, then translates the findings into a bedside-usable framework.

The Evidence Landscape: What 56 Studies Actually Show

Most of the published literature on statin deprescribing is observational rather than experimental, with real-world database studies accounting for nearly two-thirds of included reports.

Only about one in nine studies was a randomized controlled trial, underscoring how much of current practice rests on real-world rather than experimental evidence.

Distribution of Study Designs Among 56 Included Statin-Deprescribing Studies

Real-world studies

65%

Narrative reviews

17%

Randomized trials

11%

Systematic reviews

9%

Case report

2%

Source: systematic review of statin deprescribing literature, Internal Medicine Journal, 2026.

Database analyses of clinical, administrative, and quality-of-life outcomes were the dominant assessment tool, used in roughly six of every ten studies.

Notably, about four in ten studies reported favorable outcomes after deprescribing, with discontinuation generally unassociated with serious adverse events and frequently linked to better quality of life.

A multidisciplinary team — typically physicians, pharmacists, and nurses working together — carried out the deprescribing intervention in 43% of cases, reinforcing that this is rarely a single-clinician decision.

The Strongest Signal: A 2026 Meta-Analysis Across 33,000 Patients

A separate systematic review and meta-analysis published in BMC Geriatrics pooled 15 studies of preventive-medication deprescribing — including statins, antihypertensives, anticoagulants, and antidiabetic agents — in frail, demented, or terminally ill older adults.

From over 10,000 initial records, the analysis ultimately included 15 studies representing more than 33,000 participants with mean ages ranging from the mid-60s to roughly 95 years.

Pooled across all drug classes, deprescribing was not associated with a statistically significant increase in all-cause mortality, hospitalization, or major adverse cardiovascular events.

When the analysis was restricted to randomized trials alone, the mortality signal tightened further, with no meaningful difference between deprescribing and continuation groups.

Pooled Relative Risk (95% CI) — Deprescribing vs. Continuation

All-cause mortality

Hospitalization

MACE

RR 0.5RR 1.0 (no difference)RR 2.0+

Each point estimate's confidence interval crosses RR 1.0, indicating no statistically significant difference between deprescribing and continuation across all 15 pooled studies. Data: BMC Geriatrics, 2026.

The certainty of this evidence was rated very low by GRADE criteria, and the authors were explicit that further high-quality studies are still needed.

Deprescribing also showed no increased risk of fracture or fall, and antihypertensive deprescribing specifically produced only a modest, clinically negligible rise in systolic blood pressure.

The Defining Trial: Statin Discontinuation in Advanced Illness

The most influential single study in this field remains a multicenter, pragmatic randomized clinical trial of statin discontinuation in patients with an estimated life expectancy of one month to one year.

Investigators enrolled 381 patients who had been on statin therapy for at least three months and had no recent active cardiovascular disease, randomizing them to discontinue or continue treatment.

Death within 60 days, the primary outcome, occurred in 23.8% of the discontinuation group versus 20.3% of the continuation group — a difference that was not statistically significant.

Quality of life, measured by a standard palliative-care instrument, was significantly better in the group that stopped statins.

Fewer than 5% of patients in either arm experienced a cardiovascular event during follow-up, and discontinuation produced an estimated cost savings of roughly $3.37 per patient per day.

Table 1. Key Outcomes From the Pivotal Statin-Discontinuation RCT in Advanced, Life-Limiting Illness

Outcome	Discontinuation arm	Continuation arm	Statistical significance
60-day mortality (primary endpoint)	23.8%	20.3%	Not significant (P = 0.36)
Cardiovascular events	<5%	<5%	No meaningful difference
Quality-of-life score (McGill QOL)	7.11	6.85	Significant favoring discontinuation (P = 0.04)
Estimated savings per patient	~$716 over the study period		—

One important caveat belongs here, in the interest of balance: noninferiority for the primary endpoint was not formally met, because the trial's confidence interval extended slightly beyond the prespecified margin even though the point estimate favored no harm.

That nuance is why most experts describe the evidence as reassuring rather than definitive, and why shared decision-making — not blanket protocol — remains the standard.

A Practical Deprescribing Algorithm

The Canadian deprescribing.org consortium has formalized a stepwise statin deprescribing algorithm that mirrors the logic emerging from this literature.

The algorithm starts by asking whether the patient is taking a statin for primary or secondary prevention, since the calculus differs meaningfully between the two.

It then layers in life expectancy, frailty status, and the patient's own priorities — pill burden versus residual cardiovascular risk reduction — before recommending continuation, dose reduction, or discontinuation.

Patients with a Clinical Frailty Scale score of 4 or higher were largely excluded from the randomized evidence base, which means decisions in this group lean more heavily on shared values than on hard trial data.

Reasonable Candidates for a Deprescribing Conversation

Life expectancy under approximately one year from any cause is the clearest trigger identified across the reviewed literature.

Advanced dementia or severe functional dependence, where the time-to-benefit of statin therapy plausibly exceeds remaining lifespan, is a second common trigger.

Significant statin-attributable symptoms — myalgia, fatigue, or gastrointestinal intolerance — that are eroding quality of life add further weight toward a trial of discontinuation.

Active patient preference to reduce pill burden, once risks and benefits have been discussed, is itself a valid and sufficient reason to proceed.

Patients Who Should Generally Continue

Patients with recent acute coronary syndrome, recent revascularization, or other active cardiovascular disease were excluded from the deprescribing trials and should generally remain on therapy.

Patients with a reasonably preserved life expectancy and good functional status fall outside the population this evidence was designed to address.

Generic, Brand, and Cost Considerations

One underappreciated dimension of this conversation is that statins are now overwhelmingly generic, which somewhat narrows the cost-savings argument compared with deprescribing newer, branded agents.

Table 2. Commonly Prescribed Statins: Generic and Brand Identity, Originating Manufacturer, and Representative Cash Pricing

Generic name	Brand name	Originating company (ticker)	Approx. 30-day cash price
Atorvastatin	Lipitor	Pfizer (NYSE: PFE)	$4–$11 generic; brand savings card as low as $4
Rosuvastatin	Crestor	AstraZeneca (NYSE: AZN)	$10–$20 generic
Simvastatin	Zocor	Merck (NYSE: MRK)	$4–$10 generic
Pravastatin	Pravachol	Bristol-Myers Squibb (NYSE: BMY)	$4–$12 generic

Generic atorvastatin alone is among the most prescribed drugs in the United States, with cash prices as low as $4 for a 30-day supply at major retail pharmacy discount programs.

For most patients, the rationale for deprescribing is therefore symptom burden, pill count, and goals-of-care alignment rather than direct drug cost — though caregiver and system-level savings from reduced monitoring, lab draws, and visit complexity remain real.

As of this writing, Pfizer (PFE) traded near $24 per share and AstraZeneca (AZN) traded near $189 per share; both figures are provided for general financial-education context only and change daily.

Case Vignette

An 84-year-old woman with metastatic pancreatic cancer and an estimated prognosis of four to six months is admitted for malaise and poor appetite.

Her medication list includes atorvastatin 40 mg, started a decade earlier for primary prevention, alongside ten other chronic medications.

She has no history of myocardial infarction, stroke, or revascularization, and her family reports that pill-taking has become physically exhausting for her.

Applying the framework above, her limited life expectancy, absence of active cardiovascular disease, and clearly stated preference to reduce pill burden together support a shared decision to discontinue the statin, ideally documented after a brief conversation about residual (small) cardiovascular risk.

What Remains Uncertain

The certainty of evidence behind these recommendations is consistently graded as low to very low, a limitation the review authors themselves emphasize.

Follow-up periods across the pooled studies ranged from sixteen weeks to six years, which may not be long enough to capture delayed vascular events after stopping a statin.

Almost none of the underlying studies were powered specifically for cardiovascular mortality as a primary endpoint, which is why guideline bodies have been slow to issue formal statin deprescribing recommendations.

Ongoing and future randomized trials, rather than additional retrospective database studies, are what the field most needs to move this from a reasonable practice to a guideline-backed standard.

Bottom Line

In patients with a life expectancy of roughly one year or less, advanced frailty, or dementia, the cumulative evidence — though still low-certainty — does not show increased mortality or cardiovascular events from stopping a statin, and quality of life may improve.

Decisions should remain individualized, ideally multidisciplinary, and anchored in the patient's own goals rather than applied as a blanket protocol.

Patients with recent or active cardiovascular disease fall outside this evidence base and should generally continue therapy.

References

1. Statin deprescribing: a comprehensive review and development of a clinical algorithm for optimal patient management. Internal Medicine Journal, 2026.
2. Deprescribing preventive medications in older adults with advanced frailty, dementia, or limited life expectancy: a systematic review and meta-analysis. BMC Geriatrics, 2026.
3. Safety and Benefit of Discontinuing Statin Therapy in the Setting of Advanced, Life-Limiting Illness: A Randomized Clinical Trial. American College of Cardiology journal scan summary.
4. Statin Evidence-Based Deprescribing Guideline and Algorithm. Deprescribing.org / Canadian Deprescribing Network.
5. Atorvastatin Pricing and Coupons. GoodRx, 2026.
6. Statins. MedlinePlus, National Library of Medicine.

This article is intended for physician education and general clinical discussion only; it does not constitute individualized medical advice and should not replace clinical judgment, institutional guidelines, or shared decision-making with individual patients. Drug pricing and stock data are approximate, change frequently, and are provided for general financial-education context rather than investment or prescribing guidance.

The ASM Miscount: Why Roughly 500 Cardiologists May Be on a Mandatory Payment List They Don't Belong On

Health Policy & Practice Economics

Cardiology Blog | Policy Brief | Updated June 2026

A new mandatory Medicare payment model for heart failure has a list problem, and the list determines who is financially exposed starting in 2027.

The Ambulatory Specialty Model, known as ASM, was finalized by the Centers for Medicare and Medicaid Services as part of the 2026 Medicare Physician Fee Schedule.

ASM is designed to hold general cardiologists financially accountable for the longitudinal, outpatient management of heart failure, alongside a parallel track for low back pain specialists.

The model deliberately excludes interventional cardiology, electrophysiology, and advanced heart failure and transplant specialists, restricting participation to general cardiology.

According to the American College of Cardiology, that exclusion criterion was not applied correctly when CMS generated its preliminary participant roster.

Society leadership has stated that roughly 500 of the approximately 2,600 cardiologists on the preliminary list were flagged as misclassified, including subspecialists CMS itself says should be exempt.

This matters because ASM is a two-sided risk model, meaning every included physician is exposed to both upside and downside payment adjustments on Medicare Part B claims.

Figure 1 · ASM Payment Adjustment Range, First Payment Year (2029)

Top performer

+9%

Median performer

0%

Bottom performer

−9%

Source: CMS ASM Model Overview Factsheet. Adjustments apply to all Part B allowed charges, not only heart-failure-related services, and the range may widen in later payment years.

What Went Wrong With the List

CMS built the preliminary ASM roster from historical Medicare claims, identifying physicians who treated at least 20 original Medicare beneficiaries with heart failure over a 12-month lookback period within a selected geographic area.

The intent, per CMS, was to capture general cardiology exclusively, since interventional, electrophysiology, and advanced heart failure colleagues already operate under different cost and referral patterns that the model isn't designed to evaluate.

Claims-based specialty tagging is imperfect, and a cardiologist who bills certain procedural or device codes can still carry a general cardiology taxonomy code in CMS's enrollment system.

That mismatch appears to be the root cause, and it means a physician's actual clinical focus may diverge from how CMS's claims algorithm classified them.

The ACC has formally raised these discrepancies with CMS and is pushing for a transparent, standing correction process rather than a one-time fix.

No such formal appeals mechanism exists yet, which is itself part of the advocacy ask.

Who Should Check the List, and How

Every general cardiologist who treats a meaningful outpatient heart failure panel under original Medicare should confirm their own status rather than assume they are uninvolved.

The preliminary ASM participant dataset is searchable by NPI on CMS's public data portal.

Physicians who believe they were included in error, particularly interventionalists, electrophysiologists, and advanced heart failure or transplant cardiologists, are urged to contact CMS directly at AmbulatorySpecialtyModel@cms.hhs.gov.

The final participant list is expected in late summer 2026, ahead of the model's January 1, 2027 launch.

Employed physicians, including those at large academic or hospital-affiliated systems, should also ask their division or department leadership whether group-level compensation formulas reference CMS Innovation Center model performance, since wRVU-based plans were not built with episode-based payment adjustments in mind.

Figure 2 · ASM Implementation Timeline

November 2025

CMS finalizes ASM in the CY2026 Medicare Physician Fee Schedule.

Early 2026

CMS releases mandatory geographic areas and a preliminary participant list.

June 2026

ACC identifies roughly 500 misclassified specialists and urges a formal CMS correction process.

Late Summer 2026

Final ASM participant list is published.

Jan 1, 2027 – Dec 31, 2031

Five ASM performance years; payment adjustments apply 2029–2033.

What CMS Will Actually Measure

Once finalized, ASM evaluates each general cardiologist across four domains: quality, cost, care improvement activities, and interoperability, modeled on the existing MIPS Value Pathways framework.

Within quality, CMS has signaled that blood pressure control and adherence to guideline-directed medical therapy for reduced ejection fraction will be central measures.

That places a familiar drug bundle squarely under financial scrutiny: beta-blockers, renin-angiotensin system inhibitors, mineralocorticoid receptor antagonists, and SGLT2 inhibitors.

Patient-reported outcome measures are also part of the model, which is a reporting workflow many general cardiology practices have not yet built or licensed.

Specialty	ASM Status	Rationale
General cardiology	Included	Primary outpatient manager of chronic HF under Original Medicare
Interventional cardiology	Excluded	Procedure-driven cost and referral pattern, not longitudinal HF management
Electrophysiology	Excluded	Device and arrhythmia focus falls outside the model's HF episode design
Advanced HF / transplant cardiology	Excluded	Manages the highest-acuity HF subset the model was not designed to risk-adjust for

The Guideline-Directed Therapy Bundle Under the Microscope

Because ASM's quality score leans on whether reduced-ejection-fraction patients are on appropriate therapy, documentation and prescribing patterns now carry direct payment consequences.

Among the four pillars, the angiotensin receptor-neprilysin inhibitor class has the most complex cost landscape for patients and practices to navigate.

Novartis (NYSE: NVS) markets the branded ARNI Entresto (sacubitril/valsartan), which lost patent exclusivity in 2025, opening the door to lower-cost generic sacubitril/valsartan alternatives.

Brand-name Entresto still lists at roughly $600 to $700 per 30-day supply at retail, while generic sacubitril/valsartan is now available for as little as $45 to $50 per month with a standard pharmacy discount card.

Medicare Part D beneficiaries also benefit from an Inflation Reduction Act negotiated price of approximately $295 per month for the brand product, effective 2026.

For practices building ASM-ready prescribing protocols, knowing the generic option exists is now a quality-and-cost lever, not just a patient-affordability conversation.

Drug Class	Generic	Common Brand	Approx. Monthly Cost	Manufacturer
Beta-blocker	Carvedilol / metoprolol succinate	Coreg / Toprol-XL	$4–$15 (generic)	Multiple generic manufacturers
ACE inhibitor	Lisinopril	Zestril	$4–$10 (generic)	Multiple generic manufacturers
ARNI	Sacubitril/valsartan	Entresto	$45–$50 (generic) / $600–$700 (brand)	Novartis (NVS)
MRA	Spironolactone	Aldactone	$4–$12 (generic)	Multiple generic manufacturers

Case Vignette

A general cardiologist employed by an academic health system has historically managed roughly 150 Medicare patients with heart failure with reduced ejection fraction each year.

The physician learns their practice city is in a selected ASM region and assumes participation is automatic and unavoidable.

A search of the CMS participant dataset by NPI confirms inclusion, prompting the physician to audit current prescribing for the four-pillar guideline-directed therapy bundle.

The audit reveals several patients are still on legacy ACE inhibitor monotherapy without an ARNI or SGLT2 inhibitor trial, a gap that would directly lower the quality score once performance years begin.

The physician also confirms with division leadership whether the employer's wRVU compensation formula will pass through any ASM payment adjustment, since that detail is not standardized across institutions.

Why This Reaches Beyond the 500

Even cardiologists confident in their own classification should treat this episode as an early signal about ASM's operational maturity.

A claims-based algorithm mis-tagging 500 physicians on a first pass suggests the underlying attribution logic, the same logic that will assign patients and calculate cost benchmarks, is still being refined.

Practices in selected geographic areas have a narrow window before the late-summer 2026 final list to verify documentation, build PROM collection infrastructure, and confirm compensation-plan interactions with division leadership.

Bottom Line

Roughly 500 cardiologists may be on a mandatory CMS payment list they don't belong on, and the correction window is open now, not after the final list ships in late summer 2026.

Every general cardiologist in a selected region should verify NPI status on the CMS participant dataset, confirm guideline-directed therapy documentation for HFrEF patients, and ask employer leadership how ASM adjustments interact with wRVU compensation.

References

1. Centers for Medicare and Medicaid Services. ASM (Ambulatory Specialty Model) overview page.
2. CMS Innovation Center. ASM Model Overview Factsheet (PDF).
3. CMS. ASM Frequently Asked Questions.
4. American College of Cardiology. Ambulatory Specialty Model for Heart Failure advocacy hub.
5. CMS. ASM Participants dataset (searchable by NPI).
6. GoodRx. Entresto (sacubitril/valsartan) pricing.

This article is intended for physician education on healthcare policy and practice economics, and does not constitute legal, financial, or compensation advice. Clinicians should confirm their individual ASM participation status directly with CMS and consult their institution's compliance and contracting offices regarding compensation-formula implications.

Sector Atlas · Updated June 30, 2026

The Healthcare & MedTech Stock Atlas

Every major publicly traded U.S. healthcare specialty, mapped with live analyst sentiment, direct company links, sample portfolios from aggressive to conservative, and the emerging names with the most exponential upside.

❤️ Cardiology & Cardiovascular Surgery 🦴 Orthopedics 🔬 Diagnostics & Imaging 🤖 Surgical Robotics 💊 Large-Cap Pharma 🧬 Biotech 🛡️ Managed Care 🏥 Hospitals 💻 Healthcare IT 🩸 Diabetes Care 🦷 Dental & Vision ✅ All Buy Ratings 📊 Sample Portfolios 🎗 Oncology 🧠 Neurology & CNS 🫁 Respiratory & Sleep 🦋 Rare Disease 🐾 Animal Health 🌸 Women’s Health 🫀 GI & Gastroenterology 💧 Renal & Nephrology 🚀 Emerging Growth

Before you read on: this page is for general informational and educational purposes only. It is not investment advice, and the author is not a financial advisor. Analyst consensus ratings and price targets are time-sensitive snapshots, sourced from stockanalysis.com, TipRanks, MarketBeat, Public.com, and Simply Wall St as of June 29–30, 2026, and can shift within days around earnings or FDA news. On the new "Price" column: bolded values are recent reference prices captured during research; every other ticker links straight to a live quote instead of showing a number that could already be stale. Always verify current data before acting, and speak with a licensed advisor about your own situation.

1

Cardiology & Cardiovascular Devices

Pacemakers, stents, structural heart valves, and the surgical robots edging into the cath lab.

Ticker	Company	Cap	Rating	Price	Target	What they do
MDT	Medtronic	Large	Buy	$81	~$98–$108	Pacemakers, defibrillators, cardiac ablation tech
ABT	Abbott Laboratories	Large	Buy	$92.71	~$128	Cardiovascular, diabetes & diagnostics conglomerate
BSX	Boston Scientific	Large	Hold	$42.47	~$115–$130	Electrophysiology (FARAPULSE), structural heart (WATCHMAN)
EW	Edwards Lifesciences	Large	Mixed	$90.71	—	Structural heart valves (TAVR), critical care monitoring
ATRC	AtriCure	Small	Mixed	Check live price	—	Atrial fibrillation surgical ablation devices
CRDL	Cardiol Therapeutics	Small	Strong Buy	$0.99	~$8	Clinical-stage CBD-based anti-inflammatory heart drugs
OBIO	Orchestra BioMed	Small	Speculative	Check live price	—	Bioelectronic hypertension therapy (AVIM), partnered with Medtronic
JNJ	Johnson & Johnson (Abiomed & Shockwave)	Large	Buy	$254	~$257	Owns Impella heart pumps (Abiomed) and intravascular lithotripsy (Shockwave) for calcified artery treatment
PEN	Penumbra ⚠ Acq. by BSX Jan 2026	Mid	Buy-leaning	$317.63	—	Thrombectomy systems for vascular and neurovascular clot removal
NARI	Inari Medical	Mid	Buy-leaning	Check live price	—	Catheter-based devices to remove blood clots in venous thromboembolism (DVT/PE)
SILK	Silk Road Medical	Small	Mixed	Check live price	—	TransCarotid Artery Revascularization (TCAR) system for stroke prevention
AORT	Artivion (formerly CryoLife)	Small/Mid	Buy-leaning	Check live price	—	Aortic disease devices, cardiac surgery grafts, and tissue products
LIVN	LivaNova	Mid	Mixed	Check live price	—	Cardiopulmonary bypass/perfusion systems used in open-heart surgery
HAE	Haemonetics	Mid	Buy-leaning	Check live price	—	Blood management and autotransfusion systems used during cardiac surgery
MMSI	Merit Medical Systems	Small/Mid	Buy-leaning	Check live price	—	Cardiovascular catheters, guidewires, and embolization devices
ANGO	AngioDynamics	Small	Mixed	Check live price	—	Vascular access devices, peripheral vascular and venous disease treatment
SRDX	Surmodics	Small	Mixed	Check live price	—	Drug-coated balloon technology and coatings licensed to cardiovascular device makers
ITGR	Integer Holdings	Mid	Buy-leaning	Check live price	—	Manufactures components (batteries, leads) used inside pacemakers and defibrillators
IRTC	iRhythm Technologies	Small/Mid	Buy-leaning	Check live price	—	Zio wearable patch for ambulatory cardiac arrhythmia monitoring
CNMD	CONMED	Small/Mid	Mixed	Check live price	—	Surgical devices used across cardiac and general surgery procedures
INSP	Inspire Medical Systems	Mid	Buy-leaning	$41.75	—	Implantable neurostimulation for sleep apnea, a major cardiovascular risk factor
GETI-B.ST	Getinge (Stockholm-listed)	Mid/Large	Mixed	Check live price	—	Cardiopulmonary support, intra-aortic balloon pumps, surgical workflow equipment

2

Orthopedics

Joint replacements, spine hardware, and the robotic navigation systems reshaping the OR.

Ticker	Company	Cap	Rating	Price	Target	What they do
SYK	Stryker	Large	Buy	$304.69	—	Orthopedic implants, Mako robotics, MedSurg
ZBH	Zimmer Biomet	Mid/Large	Hold	$93	~$98–$103	Knee/hip implants, ROSA robotics, spine, dental
JNJ	J&J DePuy Synthes	Large	Buy	$254	~$257	Orthopedic reconstruction & trauma
GMED	Globus Medical	Mid	Buy-leaning	Check live price	—	Spine implants, ExcelsiusGPS robotic spine surgery
SNN	Smith+Nephew	Mid	Hold	Check live price	—	Orthopedics, sports medicine, wound care
AXGN	Axogen	Small	Buy-leaning	Check live price	—	Peripheral nerve repair
ATEC	Alphatec Holdings	Small	Buy-leaning	Check live price	—	Spine surgery technology
ENOV	Enovis	Mid	Mixed	Check live price	—	Reconstructive & prevention/recovery orthopedics

3

Diagnostics & Imaging

Lab testing networks, imaging centers, and the liquid-biopsy upstarts chasing earlier cancer detection.

Ticker	Company	Cap	Rating	Price	Target	What they do
DGX	Quest Diagnostics	Large	Mixed (Hold-leaning)	$195	~$190–$220	Nationwide clinical lab testing
LH	Labcorp	Large	Buy-leaning	Check live price	—	Lab testing & drug development services
GEHC	GE HealthCare	Large	Buy-leaning	$63.72	—	MRI, CT, ultrasound imaging equipment
TMO	Thermo Fisher Scientific	Large	Buy	Check live price	—	Life sciences tools, diagnostics, lab equipment
DHR	Danaher	Large	Buy-leaning	Check live price	—	Diagnostics, life sciences, biotech tools
RDNT	RadNet	Small/Mid	Buy-leaning	$58	—	Outpatient imaging + AI imaging division
GH	Guardant Health	Mid	Buy	$140	—	Liquid biopsy cancer genomic testing
EXAS	Exact Sciences	Mid	Buy-leaning	Check live price	—	Cancer screening (Cologuard)
NTRA	Natera	Mid	Buy	Check live price	—	Genetic testing, prenatal & oncology
TXG	10x Genomics	Small	Mixed	Check live price	—	Single-cell and spatial genomics tools

4

Surgical Robotics & Broad MedTech

The da Vinci-class platforms hospitals are betting their capital budgets on.

Ticker	Company	Cap	Rating	Price	Target	What they do
ISRG	Intuitive Surgical	Large	Strong Buy	$412	~$580–$615	da Vinci & Ion robotic surgical platforms
MDT	Medtronic	Large	Buy	$81	~$98–$108	Hugo robotic-assisted surgery system
SYK	Stryker	Large	Buy-leaning	$304.69	—	Mako robotic orthopedic surgery
ZBH	Zimmer Biomet	Mid/Large	Hold	$93	~$98–$103	ROSA robotic knee/hip navigation
ASXC	Asensus Surgical	Small	Speculative	Check live price	—	Digital laparoscopic surgical robotics
TMDX	TransMedics	Mid	Buy-leaning	Check live price	—	Organ transplant preservation/logistics tech
STAA	STAAR Surgical	Small	Mixed	Check live price	—	Implantable Collamer Lens (ICL) for vision

5

Pharmaceuticals (Large-Cap)

GLP-1s, oncology blockbusters, and the patent-cliff dramas driving 2026 sentiment.

Ticker	Company	Cap	Rating	Price	Target	What they do
LLY	Eli Lilly	Large (~$700B+)	Strong Buy	$1,117	~$1,220–$1,250	GLP-1 obesity/diabetes drugs (Mounjaro, Zepbound)
JNJ	Johnson & Johnson	Large (~$565B)	Buy	$254	~$257	Diversified pharma, immunology, oncology, MedTech
ABBV	AbbVie	Large (~$383B)	Buy/Hold	Check live price	—	Immunology post-Humira (Skyrizi, Rinvoq)
MRK	Merck & Co.	Large (~$302B)	Hold	Check live price	—	Keytruda oncology franchise, facing patent cliff
AZN	AstraZeneca	Large (~$291B)	Buy-leaning	Check live price	—	Oncology, cardiovascular/metabolic, biologics
PFE	Pfizer	Large	Hold	$24.29	—	Diversified pharma, post-COVID turnaround
BMY	Bristol Myers Squibb	Large	Hold-leaning	Check live price	—	Oncology, immunology
NVO	Novo Nordisk	Large	Mixed	Check live price	—	GLP-1 drugs (Ozempic/Wegovy)
GILD	Gilead Sciences	Large	Buy-leaning	Check live price	—	HIV franchise, growing oncology (Trodelvy)
AMGN	Amgen	Large	Buy-leaning	Check live price	—	Immunology, oncology, obesity pipeline (MariTide)

6

Biotech (Mid/Small-Cap)

Gene therapy, gene editing, and the autoimmune/rare-disease names with binary catalysts ahead.

Ticker	Company	Cap	Rating	Price	Target	What they do
VRTX	Vertex Pharmaceuticals	Large	Buy	Check live price	—	Cystic fibrosis monopoly, Casgevy gene therapy
REGN	Regeneron Pharmaceuticals	Large	Buy-leaning	Check live price	—	Eylea eye drug, Dupixent (with Sanofi)
ARGX	argenx	Mid/Large	Buy	Check live price	—	FcRn blocker Vyvgart across autoimmune indications
SRPT	Sarepta Therapeutics	Mid	Hold	$18	~$19	Gene therapy for Duchenne muscular dystrophy
NTLA	Intellia Therapeutics	Small/Mid	Speculative	Check live price	—	In vivo CRISPR gene editing
CRSP	CRISPR Therapeutics	Mid	Buy	Check live price	—	Casgevy gene-editing therapy (with Vertex)
KRYS	Krystal Biotech	Mid	Buy	Check live price	—	Gene therapy gel Vyjuvek for rare skin disease
RNA	Avidity Biosciences	Small/Mid	Buy-leaning	Check live price	—	RNA-targeted therapeutics
VERA	Vera Therapeutics	Small	Speculative	Check live price	—	Autoimmune kidney disease therapeutics
XENE	Xenon Pharmaceuticals	Small/Mid	Buy	Check live price	—	KV7 channel opener for epilepsy/neuro
VKTX	Viking Therapeutics	Small/Mid	Buy	Check live price	—	Oral & injectable GLP-1 obesity candidates
CRNX	Crinetics Pharmaceuticals	Small/Mid	Buy	Check live price	—	Oral therapies for endocrine disorders
ABVX	Abivax SA	Mid	Strong Buy	$96.15 (+37% today 6/30)	~$108–$187 (avg ~$149)	French clinical-stage biotech developing obefazimod, an RNA-targeting anti-inflammatory drug in Phase 3 for ulcerative colitis; NDA filing targeted Q4 2026; 12 analysts Buy, avg target ~$149, Guggenheim $175 Best Idea

7

Managed Care & Health Insurers

Medical cost ratios, Medicare Advantage rates, and the 2026 sector-wide relief rally.

Ticker	Company	Cap	Rating	Price	Target	What they do
UNH	UnitedHealth Group	Large	Buy	Check live price	~$357–$450	Largest U.S. insurer; UnitedHealthcare + Optum
ELV	Elevance Health	Large	Buy/Neutral	Check live price	~$405	Blue Cross Blue Shield plans, Medicaid/MA
HUM	Humana	Mid/Large	Mixed	Check live price	~$210–$254	Medicare Advantage-focused insurer
CI	Cigna Group	Large	Mixed	Check live price	~$304–$400	Commercial insurance + Evernorth/Express Scripts
CVS	CVS Health	Large	Buy-leaning	Check live price	—	Retail pharmacy, Aetna insurance, Caremark PBM
CNC	Centene	Mid	Mixed	Check live price	—	Medicaid/ACA marketplace insurer
MOH	Molina Healthcare	Mid	Mixed	Check live price	—	Medicaid/Medicare/Marketplace insurer
OSCR	Oscar Health	Small	Speculative	Check live price	—	Tech-driven ACA marketplace insurer

8

Hospitals & Health Systems

For-profit hospital operators navigating Medicaid policy risk and wage inflation.

Ticker	Company	Cap	Rating	Price	Target	What they do
HCA	HCA Healthcare	Large	Buy	$315	~$415–$520	190+ acute-care hospitals across the U.S. & England
UHS	Universal Health Services	Mid/Large	Buy-leaning	Check live price	—	Acute care + behavioral health hospitals
THC	Tenet Healthcare	Mid	Mixed	$171	—	Hospitals, ambulatory surgery centers
CYH	Community Health Systems	Small	Cautious	Check live price	—	Community hospital operator
ACHC	Acadia Healthcare	Small/Mid	Mixed	$25	—	Behavioral health & substance use facilities
DVA	DaVita	Mid	Mixed	Check live price	—	Dialysis/kidney care centers
EHC	Encompass Health	Mid	Buy-leaning	Check live price	—	Inpatient rehabilitation hospitals

9

Healthcare IT & Digital Health

Clinical software, telehealth, and AI tools rapidly resetting margin expectations.

Ticker	Company	Cap	Rating	Price	Target	What they do
VEEV	Veeva Systems	Large	Buy	Check live price	—	Cloud software for life sciences (CRM, regulatory)
DOCS	Doximity	Mid	Volatile / Buy-leaning	Check live price	~$40–$65	Physician network + AI tools (DocsGPT, Scribe)
TDOC	Teladoc Health	Small/Mid	Hold/Cautious	Check live price	—	Virtual care, BetterHelp mental health platform
PHR	Phreesia	Small/Mid	Mixed	Check live price	—	Patient intake/engagement software
OMCL	Omnicell	Small/Mid	Buy-leaning	Check live price	—	Medication management automation
HQY	HealthEquity	Mid	Mixed	Check live price	—	HSA/consumer-directed healthcare accounts
WAY	Waystar Holding	Mid	Buy-leaning	Check live price	—	Healthcare payments & revenue cycle software
TEM	Tempus AI	Mid	Speculative	Check live price	—	AI-driven precision medicine platform
GDRX	GoodRx Holdings	Small	Mixed	Check live price	—	Prescription discount platform

10

Diabetes Care & Endocrinology Devices

CGMs and insulin pumps fighting the GLP-1 demand-destruction narrative.

Ticker	Company	Cap	Rating	Price	Target	What they do
DXCM	DexCom	Mid/Large	Buy	$71	~$64–$95	Continuous glucose monitoring (CGM) systems
PODD	Insulet	Mid/Large	Buy	$154	~$190	Omnipod tubeless insulin pump
TNDM	Tandem Diabetes Care	Small/Mid	Buy	$23	~$28–$31	t:slim X2 & Mobi insulin pumps
BBNX	Beta Bionics	Small	Hold/Neutral	$16	—	iLet bionic pancreas automated insulin delivery
ABT	Abbott (Diabetes Care)	Large	Buy	$92.71	~$128	FreeStyle Libre CGM franchise
SENS	Senseonics	Small	Speculative	Check live price	—	Long-term implantable CGM sensors

11

Dental & Vision

Clear aligners, contact lenses, and the eye-care names riding elective-procedure demand.

Ticker	Company	Cap	Rating	Price	Target	What they do
ALGN	Align Technology	Mid/Large	Mixed	$167	—	Invisalign clear aligners, iTero scanners
XRAY	Dentsply Sirona	Small/Mid	Mixed	$10	—	Dental equipment, consumables, technology
NVST	Envista Holdings	Mid	Buy-leaning	$30	~$28	Nobel Biocare, Ormco, DEXIS dental brands
COO	The Cooper Companies	Large	Buy-leaning	Check live price	~$91	CooperVision contact lenses, CooperSurgical
ALC	Alcon	Large	Buy-leaning	Check live price	—	Surgical & vision care eye products
BLCO	Bausch + Lomb	Mid	Mixed	Check live price	—	Eye health: surgical, vision care, pharma
HSIC	Henry Schein	Mid/Large	Hold-leaning	Check live price	—	Distributor of dental & medical products
STAA	STAAR Surgical	Small	Mixed	Check live price	—	Implantable Collamer Lens (ICL)

12

Oncology

From checkpoint inhibitors and ADCs to CAR-T, liquid biopsy, and radiation oncology — the sector with the largest pipeline of any therapeutic area.

Ticker	Company	Cap	Rating	Price	Target	What they do
MRK	Merck & Co.	Large	Buy-leaning	~$113	~$122	Keytruda (#1 selling cancer drug globally), Gardasil HPV vaccine, facing 2028 patent cliff
AZN	AstraZeneca	Large	Buy	~$86	—	Tagrisso (NSCLC), Calquence (lymphoma), Enhertu ADC (breast/gastric cancer) with Daiichi Sankyo
BMY	Bristol Myers Squibb	Large	Hold-leaning	~$60	—	Opdivo & Yervoy (I-O checkpoint inhibitors), Revlimid (blood cancer), navigating biosimilar erosion
GILD	Gilead Sciences	Large	Buy-leaning	~$116	~$145	Trodelvy ADC (breast/bladder cancer), Yescarta CAR-T (lymphoma), growing oncology franchise
NUVL	Nuvalent	Mid	Buy	—	—	Next-generation kinase inhibitors for ROS1+ and ALK+ NSCLC; highly selective brain-penetrant design
IOVA	Iovance Biotherapeutics	Mid	Buy-leaning	—	—	Amtagvi: first TIL (tumor-infiltrating lymphocyte) therapy approved by FDA for melanoma
LEGN	Legend Biotech	Mid	Buy	—	—	Carvykti BCMA CAR-T therapy (with J&J) for multiple myeloma
RVMD	Revolution Medicines	Mid	Buy	—	—	RAS(ON) inhibitors targeting KRAS-driven cancers including pancreatic and colorectal
MRUS	Merus	Small/Mid	Buy-leaning	—	—	Bispecific antibody platform; Zenocutuzumab (NRG1 fusion cancers) recently FDA-approved
ARAY	Accuray	Small	Mixed	—	—	CyberKnife and TomoTherapy radiation oncology treatment systems
NKTR	Nektar Therapeutics	Small	Mixed	—	—	IL-2 pathway immuno-oncology drug conjugates

13

Neurology & Central Nervous System (CNS)

MS, Alzheimer's, epilepsy, depression, ALS, and the gene-therapy wave reshaping neurological care.

Ticker	Company	Cap	Rating	Price	Target	What they do
BIIB	Biogen	Large	Hold-leaning	~$147	—	MS therapies (Tysabri, Tecfidera), Leqembi Alzheimer's drug (with Eisai); navigating post-aducanumab challenges
AXSM	Axsome Therapeutics	Mid	Buy	—	—	Auvelity (MDD), Sunosi (narcolepsy/hypersomnia), Symbravo (migraine); CNS commercial-stage company
ACAD	ACADIA Pharmaceuticals	Mid	Buy-leaning	—	—	Nuplazid (Parkinson's psychosis), Daybue (Rett syndrome), focused CNS rare-disease pipeline
ALKS	Alkermes	Mid	Mixed	—	—	Vivitrol (opioid/alcohol dependence), Aristada (schizophrenia), LYBALVI (schizophrenia/bipolar)
IONS	Ionis Pharmaceuticals	Mid	Buy-leaning	—	—	Antisense oligonucleotide platform; Spinraza (SMA), eplontersen (TTR amyloidosis), broad neurology pipeline
PRAX	Praxis Precision Medicine	Small/Mid	Buy	—	—	Ion channel modulators for epilepsy and neuropsychiatric disorders; multiple late-stage assets
TSHA	Taysha Gene Therapies	Small	Speculative	—	—	AAV-based gene therapies for monogenic CNS diseases including SLC13A5 deficiency
NUVB	Nuvation Bio	Small	Speculative	—	—	CNS-penetrant oncology drugs; taletrectinib for ROS1/NTRK cancers with brain metastases
XENE	Xenon Pharmaceuticals	Small/Mid	Buy	—	—	KV7 potassium channel openers for epilepsy and psychiatric disorders; Phase 3 readouts near-term

14

Respiratory & Sleep Medicine

COPD, asthma, pulmonary fibrosis, sleep apnea devices, and portable oxygen — a sector with recurring device replacement and biologics growth.

Ticker	Company	Cap	Rating	Price	Target	What they do
RMD	ResMed	Large	Buy	~$244	—	CPAP/BiPAP devices and cloud-connected respiratory care platforms for sleep apnea and COPD
VRNA	Verona Pharma	Mid	Buy	—	—	Ohtuvayre (ensifentrine) FDA-approved for COPD; first new COPD mechanism in 20 years
INGN	Inogen	Small	Mixed	—	—	Portable oxygen concentrators for chronic respiratory disease patients at home and on-the-go
INSP	Inspire Medical Systems	Mid	Buy-leaning	$41.75	—	Inspire upper-airway stimulation neurostimulator for sleep apnea patients who cannot tolerate CPAP
GERN	Geron Corporation	Small	Mixed	—	—	Rytelo (imetelstat) — telomerase inhibitor for low-risk myelodysplastic syndromes; first approved telomerase inhibitor
LUNG	Pulmonx	Small	Mixed	—	—	Zephyr Endobronchial Valve for minimally invasive treatment of severe emphysema
GOSS	Gossamer Bio	Small	Speculative	—	—	Seralutinib inhaled therapy for pulmonary arterial hypertension; Phase 3 stage

15

Rare Disease & Orphan Drugs

High-price, high-margin therapies for ultra-rare conditions — pricing power, limited competition, and faster FDA pathways define this sub-sector.

Ticker	Company	Cap	Rating	Price	Target	What they do
BMRN	BioMarin Pharmaceutical	Large	Buy-leaning	—	—	Enzyme replacement and gene therapies for rare genetic diseases: PKU, hemophilia A (Roctavian), achondroplasia
RARE	Ultragenyx Pharmaceutical	Mid	Buy	—	—	Rare metabolic diseases; Crysvita (XLH), Dojolvi (LC-FAOD), Evkeeza (homozygous familial hypercholesterolemia)
PTCT	PTC Therapeutics	Mid	Mixed	—	—	Translarna (Duchenne muscular dystrophy), Translarna gene-therapy pipeline, rare neurological disorders
ARWR	Arrowhead Pharmaceuticals	Mid	Buy	—	—	RNAi therapeutics for rare liver disease (plozasiran for hypertriglyceridemia), respiratory, and cardiometabolic
ALNY	Alnylam Pharmaceuticals	Large	Buy	—	—	RNAi pioneer; Onpattro, Givlaari, Oxlumo, Amvuttra (TTR amyloidosis cardiomyopathy) and growing commercial portfolio
SRPT	Sarepta Therapeutics	Mid	Hold	~$18	~$19	Elevidys gene therapy and exon-skipping drugs for Duchenne muscular dystrophy; safety overhang on stock
BLUE	bluebird bio	Small	Speculative	—	—	Gene therapies for beta-thalassemia (Zynteglo) and sickle cell disease (Lyfgenia); commercialization-stage
SWTX	SpringWorks Therapeutics	Small/Mid	Buy-leaning	—	—	Ogsiveo (nirogacestat) for desmoid tumors; gamma-secretase inhibitor platform for rare oncology

16

Animal Health & Veterinary

Companion animal and livestock medicines, diagnostics, and vaccines — insulated from human drug pricing pressures and driven by pet-humanization trends.

Ticker	Company	Cap	Rating	Price	Target	What they do
ZTS	Zoetis	Large	Buy	~$183	—	World's largest animal health company: medicines, vaccines, diagnostics for livestock and companion animals
IDXX	IDEXX Laboratories	Large	Buy	—	—	In-house veterinary diagnostics (IDEXX Catalyst, ProCyte), reference labs, and point-of-care testing
ELAN	Elanco Animal Health	Mid	Hold	—	—	Companion animal and farm animal products; Credelio (parasiticide), Galliprant (canine pain)
PETQ	PetIQ	Small	Mixed	—	—	Affordable pet health and wellness products through retail and veterinary service distribution
PAHC	Phibro Animal Health	Small	Mixed	—	—	Medicated feed additives, vaccines, and performance enhancers for livestock and poultry

17

Women’s Health & Fertility

Contraception, fertility, menopause, endometriosis, and PCOS — historically underinvested specialty now attracting significant capital.

Ticker	Company	Cap	Rating	Price	Target	What they do
PGNY	Progyny	Mid	Buy-leaning	—	—	Fertility benefits management platform for employers; smart bundles covering IVF, egg freezing, surrogacy
HIMS	Hims & Hers Health	Small/Mid	Buy-leaning	—	—	Direct-to-consumer telehealth platform for men’s and women’s health (hair loss, sexual health, weight management)
DARE	Dare Bioscience	Small	Speculative	—	—	Women’s health drug pipeline: endometriosis, contraception, vaginal health therapeutics
MYOV	Myovant Sciences (now part of Sumitovant)	Large	Acquired	—	—	Myfembree/Orgoviyx (relugolix) for uterine fibroids and endometriosis; fully acquired by Sumitomo in 2023
ABBV	AbbVie (Orilissa/Oriahnn)	Large	Buy/Hold	~$195	—	Orilissa (endometriosis), Oriahnn (uterine fibroids) in addition to immunology blockbusters

18

Gastrointestinal & Inflammatory Bowel Disease

IBD biologics, NASH, liver disease, and the emerging RNA/small-molecule alternatives to TNF inhibitors.

Ticker	Company	Cap	Rating	Price	Target	What they do
ABVX	Abivax SA	Mid	Strong Buy	$96.15 (+37% 6/30)	~$108–$187 (avg ~$149)	Obefazimod Phase 3 for ulcerative colitis (NDA Q4 2026 target); RNA-based anti-inflammatory mechanism; remarkable 1,157% 1-yr gain
SYRE	Spyre Therapeutics	Small	Buy	—	~$115	Extended-half-life anti-integrin antibodies for IBD (Crohn’s & UC); Deutsche Bank initiated Buy $115 target
MDGL	Madrigal Pharmaceuticals	Mid	Buy	—	—	Rezdiffra (resmetirom) — first and only FDA-approved drug for NASH/MASH liver disease
ETNB	89bio	Small	Buy-leaning	—	—	Pegozafermin FGF21 analog for MASH and hypertriglyceridemia; Phase 3 stage
GILD	Gilead Sciences (liver)	Large	Buy-leaning	~$116	~$145	Hepatitis B & C treatments; seladelpar and GS-1670 for NASH; dominant viral liver disease franchise
ARWR	Arrowhead Pharmaceuticals	Mid	Buy	—	—	RNAi plozasiran targeting liver triglyceride production; NASH pipeline expansion

19

Renal & Nephrology

Dialysis services, IgA nephropathy, polycystic kidney disease, and the SGLT2 inhibitor wave redefining CKD management.

Ticker	Company	Cap	Rating	Price	Target	What they do
DVA	DaVita	Mid	Mixed	—	—	Largest independent U.S. kidney care/dialysis center network; outpatient and home dialysis
VERA	Vera Therapeutics	Small	Speculative	—	—	Atacicept TACI-Fc fusion protein for IgA nephropathy and lupus nephritis; Phase 3 ORIGIN trial
CALT	Calliditas Therapeutics	Small	Mixed	—	—	Tarpeyo/Nefecon (budesonide) FDA-approved for IgA nephropathy; first targeted therapy for this kidney disease
TVTX	Travere Therapeutics	Small	Buy-leaning	—	—	Filspari (sparsentan) for IgA nephropathy and FSGS; first non-immunosuppressant approved for IgAN
OTSKF	Otsuka Holdings (OTC)	Large	Mixed	—	—	Jynarque (tolvaptan) for autosomal dominant polycystic kidney disease (ADPKD)
KDNY	Chinook Therapeutics (now part of Novartis)	Small	Acquired 2023	—	—	Zibotentan/dapagliflozin combination for IgAN — pipeline assets acquired by Novartis in 2023

✅ BUY RATINGS

All 81 Companies with Buy or Strong Buy Consensus

Every company across all 19 specialties currently carrying a Buy or Strong Buy analyst consensus, sorted by conviction (Strong Buy → Buy → Buy-leaning) then alphabetically. Prices & targets as of June 29–30, 2026. Not investment advice. Not a recommendation to buy or sell.

#	TICKER	COMPANY	SPECIALTY	CAP	RATING	PRICE (Jun 30)	ANALYST TARGET	WHAT THEY DO
1	ABVX	Abivax SA	🧬 Biotech	Mid	Strong Buy	$96.15 (+37% today 6/30)	~$108–$187 (avg ~$149)	French clinical-stage biotech developing obefazimod, an RNA-targeting anti-inflammatory drug in Phase 3 for ul
2	CRDL	Cardiol Therapeutics	❤️ Cardiology	Small	Strong Buy	$0.99	~$8	Clinical-stage CBD-based anti-inflammatory heart drugs
3	ISRG	Intuitive Surgical	🤖 Robotics/MedTech	Large	Strong Buy	$412	~$580–$615	da Vinci & Ion robotic surgical platforms
4	LLY	Eli Lilly	💊 Large-Cap Pharma	Large (~$700B+)	Strong Buy	$1,117	~$1,220–$1,250	GLP-1 obesity/diabetes drugs (Mounjaro, Zepbound)
5	ABT	Abbott Laboratories	❤️ Cardiology	Large	Buy	$92.71	~$128	Cardiovascular, diabetes & diagnostics conglomerate
6	ALNY	Alnylam Pharmaceuticals	🦋 Rare Disease	Large	Buy	—	—	RNAi pioneer; Onpattro, Givlaari, Oxlumo, Amvuttra (TTR amyloidosis cardiomyopathy) and growing commercial por
7	ARGX	argenx	🧬 Biotech	Mid	Buy	Check live price	—	FcRn blocker Vyvgart across autoimmune indications
8	ARWR	Arrowhead Pharmaceuticals	🦋 Rare Disease	Mid	Buy	—	—	RNAi therapeutics for rare liver disease (plozasiran for hypertriglyceridemia), respiratory, and cardiometabol
9	AXSM	Axsome Therapeutics	🧠 Neurology/CNS	Mid	Buy	—	—	Auvelity (MDD), Sunosi (narcolepsy/hypersomnia), Symbravo (migraine); CNS commercial-stage company
10	CRNX	Crinetics Pharmaceuticals	🧬 Biotech	Small	Buy	Check live price	—	Oral therapies for endocrine disorders
11	CRSP	CRISPR Therapeutics	🧬 Biotech	Mid	Buy	Check live price	—	Casgevy gene-editing therapy (with Vertex)
12	DXCM	DexCom	🩸 Diabetes Care	Mid	Buy	$71	~$64–$95	Continuous glucose monitoring (CGM) systems
13	GH	Guardant Health	🔬 Diagnostics	Mid	Buy	$140	—	Liquid biopsy cancer genomic testing
14	HCA	HCA Healthcare	🏥 Hospitals	Large	Buy	$315	~$415–$520	190+ acute-care hospitals across the U.S. & England
15	IDXX	IDEXX Laboratories	🐾 Animal Health	Large	Buy	—	—	In-house veterinary diagnostics (IDEXX Catalyst, ProCyte), reference labs, and point-of-care testing
16	JNJ	Johnson & Johnson (Abiomed & Shockwave)	❤️ Cardiology	Large	Buy	$254	~$257	Owns Impella heart pumps (Abiomed) and intravascular lithotripsy (Shockwave) for calcified artery treatment
17	KRYS	Krystal Biotech	🧬 Biotech	Mid	Buy	Check live price	—	Gene therapy gel Vyjuvek for rare skin disease
18	LEGN	Legend Biotech	🎗 Oncology	Mid	Buy	—	—	Carvykti BCMA CAR-T therapy (with J&J) for multiple myeloma
19	MDGL	Madrigal Pharmaceuticals	🫀 GI / IBD	Mid	Buy	—	—	Rezdiffra (resmetirom) — first and only FDA-approved drug for NASH/MASH liver disease
20	MDT	Medtronic	❤️ Cardiology	Large	Buy	$81	~$98–$108	Pacemakers, defibrillators, cardiac ablation tech
21	NTRA	Natera	🔬 Diagnostics	Mid	Buy	Check live price	—	Genetic testing, prenatal & oncology
22	NUVL	Nuvalent	🎗 Oncology	Mid	Buy	—	—	Next-generation kinase inhibitors for ROS1+ and ALK+ NSCLC; highly selective brain-penetrant design
23	PODD	Insulet	🩸 Diabetes Care	Mid	Buy	$154	~$190	Omnipod tubeless insulin pump
24	PRAX	Praxis Precision Medicine	🧠 Neurology/CNS	Small	Buy	—	—	Ion channel modulators for epilepsy and neuropsychiatric disorders; multiple late-stage assets
25	RARE	Ultragenyx Pharmaceutical	🦋 Rare Disease	Mid	Buy	—	—	Rare metabolic diseases; Crysvita (XLH), Dojolvi (LC-FAOD), Evkeeza (homozygous familial hypercholesterolemia)
26	RMD	ResMed	🫁 Respiratory	Large	Buy	~$244	—	CPAP/BiPAP devices and cloud-connected respiratory care platforms for sleep apnea and COPD
27	RVMD	Revolution Medicines	🎗 Oncology	Mid	Buy	—	—	RAS(ON) inhibitors targeting KRAS-driven cancers including pancreatic and colorectal
28	SYK	Stryker	🦴 Orthopedics	Large	Buy	$304.69	—	Orthopedic implants, Mako robotics, MedSurg
29	SYRE	Spyre Therapeutics	🫀 GI / IBD	Small	Buy	—	~$115	Extended-half-life anti-integrin antibodies for IBD (Crohn’s & UC); Deutsche Bank initiated Buy $115
30	TMO	Thermo Fisher Scientific	🔬 Diagnostics	Large	Buy	Check live price	—	Life sciences tools, diagnostics, lab equipment
31	TNDM	Tandem Diabetes Care	🩸 Diabetes Care	Small	Buy	$23	~$28–$31	t:slim X2 & Mobi insulin pumps
32	UNH	UnitedHealth Group	🛡️ Managed Care	Large	Buy	Check live price	~$357–$450	Largest U.S. insurer; UnitedHealthcare + Optum
33	VEEV	Veeva Systems	💻 Health IT	Large	Buy	Check live price	—	Cloud software for life sciences (CRM, regulatory)
34	VKTX	Viking Therapeutics	🧬 Biotech	Small	Buy	Check live price	—	Oral & injectable GLP-1 obesity candidates
35	VRNA	Verona Pharma	🫁 Respiratory	Mid	Buy	—	—	Ohtuvayre (ensifentrine) FDA-approved for COPD; first new COPD mechanism in 20 years
36	VRTX	Vertex Pharmaceuticals	🧬 Biotech	Large	Buy	Check live price	—	Cystic fibrosis monopoly, Casgevy gene therapy
37	XENE	Xenon Pharmaceuticals	🧬 Biotech	Small	Buy	Check live price	—	KV7 channel opener for epilepsy/neuro
38	ZTS	Zoetis	🐾 Animal Health	Large	Buy	~$183	—	World's largest animal health company: medicines, vaccines, diagnostics for livestock and companion animals
39	ABBV	AbbVie (Orilissa/Oriahnn)	🌸 Women's Health	Large	Buy/Hold	~$195	—	Orilissa (endometriosis), Oriahnn (uterine fibroids) in addition to immunology blockbusters
40	ACAD	ACADIA Pharmaceuticals	🧠 Neurology/CNS	Mid	Buy-leaning	—	—	Nuplazid (Parkinson's psychosis), Daybue (Rett syndrome), focused CNS rare-disease pipeline
41	ALC	Alcon	🦷 Dental & Vision	Large	Buy-leaning	Check live price	—	Surgical & vision care eye products
42	AMGN	Amgen	💊 Large-Cap Pharma	Large	Buy-leaning	Check live price	—	Immunology, oncology, obesity pipeline (MariTide)
43	AORT	Artivion (formerly CryoLife)	❤️ Cardiology	Small	Buy-leaning	Check live price	—	Aortic disease devices, cardiac surgery grafts, and tissue products
44	ATEC	Alphatec Holdings	🦴 Orthopedics	Small	Buy-leaning	Check live price	—	Spine surgery technology
45	AXGN	Axogen	🦴 Orthopedics	Small	Buy-leaning	Check live price	—	Peripheral nerve repair
46	AZN	AstraZeneca	💊 Large-Cap Pharma	Large (~$291B)	Buy-leaning	Check live price	—	Oncology, cardiovascular/metabolic, biologics
47	BMRN	BioMarin Pharmaceutical	🦋 Rare Disease	Large	Buy-leaning	—	—	Enzyme replacement and gene therapies for rare genetic diseases: PKU, hemophilia A (Roctavian), achondroplasia
48	COO	The Cooper Companies	🦷 Dental & Vision	Large	Buy-leaning	Check live price	~$91	CooperVision contact lenses, CooperSurgical
49	CVS	CVS Health	🛡️ Managed Care	Large	Buy-leaning	Check live price	—	Retail pharmacy, Aetna insurance, Caremark PBM
50	DHR	Danaher	🔬 Diagnostics	Large	Buy-leaning	Check live price	—	Diagnostics, life sciences, biotech tools
51	EHC	Encompass Health	🏥 Hospitals	Mid	Buy-leaning	Check live price	—	Inpatient rehabilitation hospitals
52	ELV	Elevance Health	🛡️ Managed Care	Large	Buy/Neutral	Check live price	~$405	Blue Cross Blue Shield plans, Medicaid/MA
53	ETNB	89bio	🫀 GI / IBD	Small	Buy-leaning	—	—	Pegozafermin FGF21 analog for MASH and hypertriglyceridemia; Phase 3 stage
54	EXAS	Exact Sciences	🔬 Diagnostics	Mid	Buy-leaning	Check live price	—	Cancer screening (Cologuard)
55	GEHC	GE HealthCare	🔬 Diagnostics	Large	Buy-leaning	$63.72	—	MRI, CT, ultrasound imaging equipment
56	GILD	Gilead Sciences	💊 Large-Cap Pharma	Large	Buy-leaning	Check live price	—	HIV franchise, growing oncology (Trodelvy)
57	GMED	Globus Medical	🦴 Orthopedics	Mid	Buy-leaning	Check live price	—	Spine implants, ExcelsiusGPS robotic spine surgery
58	HAE	Haemonetics	❤️ Cardiology	Mid	Buy-leaning	Check live price	—	Blood management and autotransfusion systems used during cardiac surgery
59	HIMS	Hims & Hers Health	🌸 Women's Health	Small	Buy-leaning	—	—	Direct-to-consumer telehealth platform for men’s and women’s health (hair loss, sexual health, wei
60	INSP	Inspire Medical Systems	❤️ Cardiology	Mid	Buy-leaning	$41.75	—	Implantable neurostimulation for sleep apnea, a major cardiovascular risk factor
61	IONS	Ionis Pharmaceuticals	🧠 Neurology/CNS	Mid	Buy-leaning	—	—	Antisense oligonucleotide platform; Spinraza (SMA), eplontersen (TTR amyloidosis), broad neurology pipeline
62	IOVA	Iovance Biotherapeutics	🎗 Oncology	Mid	Buy-leaning	—	—	Amtagvi: first TIL (tumor-infiltrating lymphocyte) therapy approved by FDA for melanoma
63	IRTC	iRhythm Technologies	❤️ Cardiology	Small	Buy-leaning	Check live price	—	Zio wearable patch for ambulatory cardiac arrhythmia monitoring
64	ITGR	Integer Holdings	❤️ Cardiology	Mid	Buy-leaning	Check live price	—	Manufactures components (batteries, leads) used inside pacemakers and defibrillators
65	LH	Labcorp	🔬 Diagnostics	Large	Buy-leaning	Check live price	—	Lab testing & drug development services
66	MMSI	Merit Medical Systems	❤️ Cardiology	Small	Buy-leaning	Check live price	—	Cardiovascular catheters, guidewires, and embolization devices
67	MRK	Merck & Co.	🎗 Oncology	Large	Buy-leaning	~$113	~$122	Keytruda (#1 selling cancer drug globally), Gardasil HPV vaccine, facing 2028 patent cliff
68	MRUS	Merus	🎗 Oncology	Small	Buy-leaning	—	—	Bispecific antibody platform; Zenocutuzumab (NRG1 fusion cancers) recently FDA-approved
69	NARI	Inari Medical	❤️ Cardiology	Mid	Buy-leaning	Check live price	—	Catheter-based devices to remove blood clots in venous thromboembolism (DVT/PE)
70	NVST	Envista Holdings	🦷 Dental & Vision	Mid	Buy-leaning	$30	~$28	Nobel Biocare, Ormco, DEXIS dental brands
71	OMCL	Omnicell	💻 Health IT	Small	Buy-leaning	Check live price	—	Medication management automation
72	PEN	Penumbra ⚠ Acq. by BSX Jan 2026	❤️ Cardiology	Mid	Buy-leaning	$317.63	—	Thrombectomy systems for vascular and neurovascular clot removal
73	PGNY	Progyny	🌸 Women's Health	Mid	Buy-leaning	—	—	Fertility benefits management platform for employers; smart bundles covering IVF, egg freezing, surrogacy
74	RDNT	RadNet	🔬 Diagnostics	Small	Buy-leaning	$58	—	Outpatient imaging + AI imaging division
75	REGN	Regeneron Pharmaceuticals	🧬 Biotech	Large	Buy-leaning	Check live price	—	Eylea eye drug, Dupixent (with Sanofi)
76	RNA	Avidity Biosciences	🧬 Biotech	Small	Buy-leaning	Check live price	—	RNA-targeted therapeutics
77	SWTX	SpringWorks Therapeutics	🦋 Rare Disease	Small	Buy-leaning	—	—	Ogsiveo (nirogacestat) for desmoid tumors; gamma-secretase inhibitor platform for rare oncology
78	TMDX	TransMedics	🤖 Robotics/MedTech	Mid	Buy-leaning	Check live price	—	Organ transplant preservation/logistics tech
79	TVTX	Travere Therapeutics	💧 Renal	Small	Buy-leaning	—	—	Filspari (sparsentan) for IgA nephropathy and FSGS; first non-immunosuppressant approved for IgAN
80	UHS	Universal Health Services	🏥 Hospitals	Mid	Buy-leaning	Check live price	—	Acute care + behavioral health hospitals
81	WAY	Waystar Holding	💻 Health IT	Mid	Buy-leaning	Check live price	—	Healthcare payments & revenue cycle software

Sample Portfolio Mixes: Aggressive → Conservative

Four illustrative healthcare-sector tilts — purely educational examples of how the names above might be combined at different risk levels. Not a recommendation. These are hypothetical allocations for discussion purposes only and ignore your personal tax situation, time horizon, and existing holdings.

AGGRESSIVE

GROWTH

BALANCED

CONSERVATIVE

🔥 Aggressive Growth Mix

High volatility · binary catalysts · small/mid-cap heavy

25%Mid/small-cap biotech — ARGX (autoimmune drug Vyvgart), CRSP (gene editing), KRYS (gene therapy), VKTX (oral GLP-1)

20%Speculative cardio & gene-therapy — CRDL, OBIO, NTLA, SRPT

20%Digital health / AI diagnostics — TEM (AI precision medicine), DOCS (physician network), GH (liquid biopsy)

15%Emerging device disruptors — BBNX (bionic pancreas), ASXC (laparoscopic robotics), TMDX (organ transport)

20%High-growth large-cap anchor — ISRG (surgical robots), LLY (GLP-1 drugs)

📈 Growth-Tilted Mix

Established growth leaders · moderate volatility

20%GLP-1 / large-cap pharma growth (LLY, NVO, VRTX)

20%Surgical robotics (ISRG, MDT)

15%Diabetes devices (DXCM, PODD)

15%Diagnostics growth (GH, NTRA, EXAS)

15%Selective mid-cap biotech (ARGX, KRYS)

15%Managed care recovery play (UNH, HUM)

⚖️ Balanced Mix

Blend of growth and ballast across specialties

20%Diversified MedTech large-caps (MDT, SYK, ABT)

20%Large-cap pharma (JNJ, LLY, MRK)

15%Managed care (UNH, ELV)

15%Hospitals (HCA, UHS)

15%Diagnostics & labs (DGX, TMO)

15%Dental/vision & diabetes devices (COO, DXCM)

🛡️ Conservative / Defensive Mix

Dividend-payers · large, diversified, lower-beta names

30%Diversified pharma dividend payers (JNJ, ABBV, PFE)

25%Mega-cap MedTech (MDT, ABT)

20%Managed care blue-chip (UNH, ELV)

15%Hospital operator with scale (HCA)

10%Diagnostics utility-like cash flow (DGX, LH)

🚀 Emerging Companies With Potential Exponential Growth

Smaller, earlier-stage names pulled from across every specialty above that carry outsized — and outsized-risk — upside according to current Street commentary. These are higher-volatility, often pre-profit or single-catalyst companies. Treat this as a watchlist starting point, not a buy list.

Cardiology

CRDL — Cardiol Therapeutics

Strong Buy consensus from a small analyst panel; speculative CBD-based anti-inflammatory cardiac pipeline with Phase 3 catalysts ahead.

Cardiology

OBIO — Orchestra BioMed

Bioelectronic hypertension therapy partnered with Medtronic; binary upside tied to BACKBEAT trial data expected 2027.

Biotech

VKTX — Viking Therapeutics

Oral & injectable GLP-1 candidates; analysts flag among the highest implied upside in cardiometabolic biotech baskets.

Biotech

CRNX — Crinetics Pharmaceuticals

Oral endocrine-disorder therapies; high implied upside in recent genomics/biotech ETF rankings.

Biotech

XENE — Xenon Pharmaceuticals

KV7 channel opener for epilepsy/depression; William Blair 2026 top pick with late-stage data readouts on deck.

Biotech

KRYS — Krystal Biotech

Commercial-stage gene therapy (Vyjuvek) with a broader redosable gene-therapy platform; William Blair top pick.

Diagnostics

GH — Guardant Health

Biggest analyst-estimate beat among diagnostics peers in recent earnings; liquid biopsy/MRD growth story.

Diagnostics

RDNT — RadNet

Outpatient imaging network layering in an AI imaging division — a structural growth story beyond pure imaging volume.

Healthcare IT

TEM — Tempus AI

AI-driven precision medicine platform; high-growth, high-volatility name at the intersection of diagnostics and software.

Healthcare IT

WAY — Waystar Holding

Revenue-cycle/payments software riding hospital AI-automation adoption.

Robotics/MedTech

TMDX — TransMedics

Organ preservation & transplant logistics — building an end-to-end transplant ecosystem with first-mover scale.

Robotics/MedTech

ASXC — Asensus Surgical

Small-cap digital laparoscopic robotics name — high-risk, early-stage challenger to the ISRG/MDT duopoly.

Orthopedics

ATEC — Alphatec Holdings

Spine-focused challenger gaining share against legacy orthopedic majors with differentiated navigation tech.

Diabetes Care

BBNX — Beta Bionics

iLet bionic pancreas — newer entrant in automated insulin delivery still scaling commercial adoption.

Dental/Vision

NVST — Envista Holdings

Fastest revenue growth of its dental peer group last quarter, with consensus price target recently raised.

Compiled June 30, 2026 from stockanalysis.com, TipRanks, MarketBeat, Public.com, Simply Wall St, Investing.com, Zacks, Yahoo Finance, StockStory, and 24/7 Wall St.
Not investment advice. Not a recommendation to buy or sell any security. The author is not a financial advisor. Ratings and targets change frequently — verify current data before acting.